The Cooper Companies Inc

There were fewer opportunities as the third quarter ended.

We're increasing our fair value estimate on the narrow-moat company to reflect higher margin assumptions.

We see attractive growth opportunities for the ophthalmology market.

Recent deals have been driven more by tax strategies than therapeutic synergies.

Those with a long-term focus will earn attractive returns as the true earnings power of this firm's growth-driving product becomes apparent during the next three years.

A handful of health-care names are selling at premiums now, but buying opportunities are surfacing, as well.

The eye-care industry may offer a respite for investors in turbulent times.